Disease on EC 1.1.98.3 - decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Infections
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832.
Infections
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis.
Infections
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-?-d-Ribose Oxidase (DprE1) Inhibitors.
Mycetoma
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis.
Tuberculosis
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1.
Tuberculosis
A Simple Work-Up-free, Solvent-free Approach to Novel Amino Acid Linked 1,4-Disubstituted 1,2,3-Triazoles as Potent Antituberculosis Agents.
Tuberculosis
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
Tuberculosis
Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis.
Tuberculosis
Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-?-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.
Tuberculosis
Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis.
Tuberculosis
Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence.
Tuberculosis
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
Tuberculosis
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832.
Tuberculosis
Crystal structure of decaprenylphosphoryl-?- D-ribose 2'-epimerase from Mycobacterium smegmatis.
Tuberculosis
Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.
Tuberculosis
Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.
Tuberculosis
DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.
Tuberculosis
Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets.
Tuberculosis
Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria.
Tuberculosis
Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening.
Tuberculosis
In silico guided design of non-covalent inhibitors of DprE1: synthesis and biological evaluation.
Tuberculosis
In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis.
Tuberculosis
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Tuberculosis
Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1.
Tuberculosis
Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Tuberculosis
Pseudomonas aeruginosa D-Arabinofuranose Biosynthetic Pathway and Its Role in Type IV Pilus Assembly.
Tuberculosis
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.
Tuberculosis
Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme.
Tuberculosis
Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.
Tuberculosis
Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
Tuberculosis
Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis.
Tuberculosis
Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
Tuberculosis
Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.
Tuberculosis
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
Tuberculosis
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.
Tuberculosis
The frequently occurring components of essential oils beta elemene and R-limonene alter expression of dprE1 and clgR genes of Mycobacterium tuberculosis H37Ra.
Tuberculosis
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Tuberculosis
Virtual screening and free energy estimation for identifying Mycobacterium tuberculosis flavoenzyme DprE1 inhibitors.
html completed